Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis

Murata,Koji; Murata,Koji; Kaji,Kosuke; Kaji,Kosuke; Nishimura,Norihisa; Nishimura,Norihisa; Enomoto,Masahide; Enomoto,Masahide; Fujimoto,Yuki; Fujimoto,Yuki; Takeda,Soichi; Takeda,Soichi; Tsuji,Yuki; Tsuji,Yuki; Fujinaga,Yukihisa; Fujinaga,Yukihisa; Takaya,Hiroaki; Takaya,Hiroaki; Kawaratani,Hideto; Kawaratani,Hideto; Namisaki,Tadashi; Namisaki,Tadashi; Akahane,Takemi; Akahane,Takemi; Yoshiji,Hitoshi; Yoshiji,Hitoshi

doi:10.3892/ijmm.2022.5157

Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis

Authors:
- Koji Murata
- Kosuke Kaji
- Norihisa Nishimura
- Masahide Enomoto
- Yuki Fujimoto
- Soichi Takeda
- Yuki Tsuji
- Yukihisa Fujinaga
- Hiroaki Takaya
- Hideto Kawaratani
- Tadashi Namisaki
- Takemi Akahane
- Hitoshi Yoshiji
View Affiliations

Affiliations: Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634‑8521, Japan
Published online on: June 9, 2022 https://doi.org/10.3892/ijmm.2022.5157
Article Number: 101
Copyright: © Murata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The gut‑liver‑muscle axis is associated with the development of sarcopenia in liver cirrhosis. The present study aimed to illustrate the combined effects of rifaximin and L‑carnitine on skeletal muscle atrophy in cirrhotic rats with steatohepatitis. For this purpose, a total of 344 Fischer rats were fed a choline‑deficient L‑amino acid‑defined (CDAA) diet with the daily oral administration of rifaximin (100 mg/kg) and/or L‑carnitine (200 mg/kg), and measurements of psoas muscle mass index and forelimb grip strength were performed. After feeding for 12 weeks, blood samples, and liver, ileum and gastrocnemius muscle tissues were harvested. The effects of L‑carnitine on rat myocytes were assessed using in vitro assays. Treatment with rifaximin attenuated hyperammonemia and liver fibrosis in the CDAA‑fed rats. Moreover, it improved intestinal permeability with the restoration of tight junction proteins and suppressed the lipopolysaccharide (LPS)‑mediated hepatic macrophage activation and pro‑inflammatory response. In addition, rifaximin prevented skeletal muscle mass atrophy and weakness by decreasing intramuscular myostatin and pro‑inflammatory cytokine levels. Moreover, rifaximin synergistically enhanced the L‑carnitine‑mediated improvement of skeletal muscle wasting by promoting the production of insulin‑like growth factor‑1 and mitochondrial biogenesis, resulting in the inhibition of the ubiquitin‑proteasome system (UPS). The in vitro assays revealed that L‑carnitine directly attenuated the impairment of mitochondrial biogenesis, thereby inhibiting the UPS in rat myocytes that were stimulated with LPS or tumor necrosis factor‑α. On the whole, the present study demonstrates that the combination of rifaximin with L‑carnitine may provide a clinical benefit for liver cirrhosis‑related sarcopenia.

View Figures

View References

1	Dasarathy S and Merli M: Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 65:1232–1244. 2016. View Article : Google Scholar : PubMed/NCBI
2	Bhanji RA, Montano-Loza AJ and Watt KD: Sarcopenia in cirrhosis: Looking beyond the skeletal muscle loss to see the systemic disease. Hepatology. 70:2193–2203. 2019. View Article : Google Scholar : PubMed/NCBI
3	Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S and Merli M: Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 75(Suppl 1): S147–S162. 2021. View Article : Google Scholar : PubMed/NCBI
4	Vasques J, Guerreiro CS, Sousa J, Pinto M and Cortez-Pinto H: Nutritional support in cirrhotic patients with sarcopenia. Clin Nutr ESPEN. 33:12–17. 2019. View Article : Google Scholar : PubMed/NCBI
5	Ebadi M, Bhanji RA, Mazurak VC and Montano-Loza AJ: Sarcopenia in cirrhosis: From pathogenesis to interventions. J Gastroenterol. 54:845–859. 2019. View Article : Google Scholar : PubMed/NCBI
6	Ascenzi F, Barberi L, Dobrowolny G, Villa Nova Bacurau A, Nicoletti C, Rizzuto E, Rosenthal N, Scicchitano BM and Musarò A: Effects of IGF-1 isoforms on muscle growth and sarcopenia. Aging Cell. 18:e129542019. View Article : Google Scholar : PubMed/NCBI
7	Nishikawa H, Enomoto H, Nishiguchi S and Iijima H: Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis. Int J Mol Sci. 21:52542020. View Article : Google Scholar :
8	West J, Gow PJ, Testro A, Chapman B and Sinclair M: Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review. J Gastroenterol Hepatol. 36:2687–2705. 2021. View Article : Google Scholar : PubMed/NCBI
9	Dos Santos ALS and Anastácio LR: The impact of L-branched-chain amino acids and L-leucine on malnutrition, sarcopenia, and other outcomes in patients with chronic liver disease. Expert Rev Gastroenterol Hepatol. 15:181–194. 2021. View Article : Google Scholar
10	Sinclair M, Grossmann M, Angus PW, Hoermann R, Hey P, Scodellaro T and Gow PJ: Low testosterone as a better predictor of mortality than sarcopenia in men with advanced liver disease. J Gastroenterol Hepatol. 31:661–667. 2016. View Article : Google Scholar
11	Ponziani FR, Picca A, Marzetti E, Calvani R, Conta G, Del Chierico F, Capuani G, Faccia M, Fianchi F, Funaro B, et al: Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia. Liver Int. 41:1320–1334. 2021. View Article : Google Scholar : PubMed/NCBI
12	Kendler BS: Carnitine: An overview of its role in preventive medicine. Prev Med. 15:373–390. 1986. View Article : Google Scholar : PubMed/NCBI
13	Houten SM, Wanders RJA and Ranea-Robles P: Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism. Biochim Biophys Acta Mol Basis Dis. 1866:1657202020. View Article : Google Scholar : PubMed/NCBI
14	Hanai T, Shiraki M, Imai K, Suetugu A, Takai K and Shimizu M: Usefulness of carnitine supplementation for the complications of liver cirrhosis. Nutrients. 12:19152020. View Article : Google Scholar :
15	Ohashi K, Ishikawa T, Hoshii A, Hokari T, Suzuki M, Noguchi H, Hirosawa H, Koyama F, Kobayashi M, Hirosawa S, et al: Effect of levocarnitine administration in patients with chronic liver disease. Exp Ther Med. 20:942020. View Article : Google Scholar : PubMed/NCBI
16	Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, Suzuki K, Nakamura A, Umemura M, Izumi T, et al: L-carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. Hepatol Commun. 2:906–918. 2018. View Article : Google Scholar : PubMed/NCBI
17	Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, et al: Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun. 3:348–355. 2019. View Article : Google Scholar : PubMed/NCBI
18	Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, et al: Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 362:1071–1081. 2010. View Article : Google Scholar : PubMed/NCBI
19	Lyon KC, Likar E, Martello JL and Regier M: Retrospective cross-sectional pilot study of rifaximin dosing for the prevention of recurrent hepatic encephalopathy. J Gastroenterol Hepatol. 32:1548–1552. 2017. View Article : Google Scholar : PubMed/NCBI
20	Rahimi RS, Brown KA, Flamm SL and Brown RS Jr: Overt hepatic encephalopathy: Current pharmacologic treatments and improving clinical outcomes. Am J Med. 134:1330–1338. 2021. View Article : Google Scholar : PubMed/NCBI
21	Kumar A, Davuluri G, Silva RNE, Engelen MPKJ, Ten Have GAM, Prayson R, Deutz NEP and Dasarathy S: Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology. 65:2045–2058. 2017. View Article : Google Scholar : PubMed/NCBI
22	Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, et al: Rifaximin alleviates endotoxemia with decreased serum levels of soluble CD163 and mannose receptor and partial modification of gut microbiota in cirrhotic patients. Antibiotics (Basel). 9:1452020. View Article : Google Scholar
23	Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y, Ozutsumi T, Furukawa M, Kitagawa K, Sato S, Nishimura N, Sawada Y, et al: Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis. Int J Mol Sci. 21:55892020. View Article : Google Scholar :
24	Demiroren K, Dogan Y, Kocamaz H, Ozercan IH, Ilhan S, Ustundag B and Bahcecioglu IH: Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. Clin Res Hepatol Gastroenterol. 38:63–72. 2014. View Article : Google Scholar
25	Horinouchi T, Hoshi A, Harada T, Higa T, Karki S, Terada K, Higashi T, Mai Y, Nepal P, Mazaki Y and Miwa S: Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells. Br J Pharmacol. 173:1018–1032. 2016. View Article : Google Scholar
26	Takeda S, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T, et al: Angiotensin receptor blockers potentiate the protective effect of branched-chain amino acids on skeletal muscle atrophy in cirrhotic rats. Mol Nutr Food Res. 65:e21005262021. View Article : Google Scholar : PubMed/NCBI
27	Doyle A, Zhang G, Abdel Fattah EA, Eissa NT and Li YP: Toll-like receptor 4 mediates lipopolysaccharide-induced muscle catabolism via coordinate activation of ubiquitin-proteasome and autophagy-lysosome pathways. FASEB J. 25:99–110. 2011. View Article : Google Scholar :
28	Girven M, Dugdale HF, Owens DJ, Hughes DC, Stewart CE and Sharples AP: l-Glutamine improves skeletal muscle cell differentiation and prevents myotube atrophy after cytokine (TNF-α) stress via reduced p38 MAPK signal transduction. J Cell Physiol. 231:2720–2732. 2016. View Article : Google Scholar : PubMed/NCBI
29	Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K and Nishiguchi S: Japan society of hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 46:951–963. 2016. View Article : Google Scholar : PubMed/NCBI
30	Gao JH, Wen SL, Tong H, Wang CH, Yang WJ, Tang SH, Yan ZP, Tai Y, Ye C, Liu R, et al: Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats. Am J Physiol Gastrointest Liver Physiol. 310:G962–G372. 2016. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
32	Shahini A, Rajabian N, Choudhury D, Shahini S, Vydiam K, Nguyen T, Kulczyk J, Santarelli T, Ikhapoh I, Zhang Y, et al: Ameliorating the hallmarks of cellular senescence in skeletal muscle myogenic progenitors in vitro and in vivo. Sci Adv. 7:eabe56712021. View Article : Google Scholar : PubMed/NCBI
33	Giusto M, Barberi L, Di Sario F, Rizzuto E, Nicoletti C, Ascenzi F, Renzi A, Caporaso N, D'Argenio G, Gaudio E, et al: Skeletal muscle myopenia in mice model of bile duct ligation and carbon tetrachloride-induced liver cirrhosis. Physiol Rep. 5:e131532017. View Article : Google Scholar : PubMed/NCBI
34	Moretti A, Paoletta M, Liguori S, Bertone M, Toro G and Iolascon G: Choline: An essential nutrient for skeletal muscle. Nutrients. 12:21442020. View Article : Google Scholar :
35	Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, et al: Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. Hepatol Res. 49:284–295. 2019. View Article : Google Scholar
36	Qiu J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan ML, Narayanan A, Eghtesad B, Mozdziak PE, McDonald C, et al: Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci USA. 110:18162–18167. 2013. View Article : Google Scholar
37	Saiman Y and Serper M: Frailty and sarcopenia in patients pre- and post-liver transplant. Clin Liver Dis. 25:35–51. 2021. View Article : Google Scholar : PubMed/NCBI
38	Gao B and Bataller R: Alcoholic liver disease: Pathogenesis and new therapeutic targets. Gastroenterology. 141:1572–1585. 2011. View Article : Google Scholar : PubMed/NCBI
39	Leung C, Rivera L, Furness JB and Angus PW: The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 13:412–425. 2016. View Article : Google Scholar : PubMed/NCBI
40	Rosa CGS, Colares JR, da Fonseca SRB, Martins GDS, Miguel FM, Dias AS, Marroni CA, Picada JN, Lehmann M and Marroni NAP: Sarcopenia, oxidative stress and inflammatory process in muscle of cirrhotic rats-action of melatonin and physical exercise. Exp Mol Pathol. 121:1046622021. View Article : Google Scholar
41	Thomsen KL, Nielsen SS, Grønbiek H, Flyvbjerg A and Vilstrup H: Effects of lipopolysaccharide endotoxin on the insulin-like growth factor I system in rats with cirrhosis. In Vivo. 22:655–661. 2008.
42	Fang WY, Tseng YT, Lee TY, Fu YC, Chang WH, Lo WW, Lin CL and Lo YC: Triptolide prevents LPS-induced skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating protein synthesis/degradation pathway. Br J Pharmacol. 178:2998–3016. 2021. View Article : Google Scholar : PubMed/NCBI
43	Sawicka AK, Hartmane D, Lipinska P, Wojtowicz E, Lysiak-Szydlowska W and Olek RA: l-Carnitine supplementation in older women. A pilot study on aging skeletal muscle mass and function. Nutrients. 10:2552018. View Article : Google Scholar :
44	Keller J, Couturier A, Haferkamp M, Most E and Eder K: Supplementation of carnitine leads to an activation of the IGF-1/PI3K/Akt signalling pathway and down regulates the E3 ligase MuRF1 in skeletal muscle of rats. Nutr Metab (Lond). 10:282013. View Article : Google Scholar
45	Patel VC, Lee S, McPhail MJW, Da Silva K, Guilly S, Zamalloa A, Witherden E, Støy S, Manakkat Vijay GK, Pons N, et al: Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 76:332–342. 2022. View Article : Google Scholar
46	Kitagawa R, Kon K, Uchiyama A, Arai K, Yamashina S, Kuwahara-Arai K, Kirikae T, Ueno T and Ikejima K: Rifaximin prevents ethanol-induced liver injury in obese KK-A^y mice through modulation of small intestinal microbiota signature. Am J Physiol Gastrointest Liver Physiol. 317:G707–G715. 2019. View Article : Google Scholar
47	Cellai L, Colosimo M, Marchi E, Venturini AP and Zanolo G: Rifaximin (L/105), a new topical intestinal antibiotic: Pharmacokinetic study after single oral administration of 3H-rifaximin to rats. Chemioterapia. 3:373–377. 1984.PubMed/NCBI